Angiex, Inc.
Angiex makes TM4SF1-directed antibody-drug conjugate (ADC) therapies for the treatment of solid cancers; our lead drug is in Phase 1 and has dosed 38 patients.
TreatmentOn the market (pre-revenue)United States
See the full profile
The pitch deck, traction, financials and competitive detail are visible to approved investors, mentors and corporates. Log in or join EndCancer.Life to request access.
Company info
- Countries of Operation
- United States
- Founding Year
- 2015
- Number of Employees
- 1–5
Company overview
- Full Description
- Angiex develops antibody-drug conjugate therapies for solid cancers that may radically decrease cancer mortality.
- Areas of focus
- Solid tumors
- Problem Statement
- Solid cancers kill nine million people per year. The dominant systemic therapies are (1) chemotherapies, which can address broad markets but have severe toxicity and only extend lifespan minimally; and (2) antibody-drug conjugates, which can have broader therapeutic margin but tend to address only slivers of the cancer market. There is a need for pan-tumor systemic therapies which can address all solid cancers like chemotherapies, but with the safety of a well designed antibody-drug conjugate. There is now an opportunity to achieve that through a novel oncology target, TM4SF1. TM4SF1-directed antibody-drug conjugates (a) kill invasive and metastatic tumor cells and (b) deprive tumors of their blood supply.
- Solution Overview
- Angiex exploits a unique biology, discovered by its founders, which is essential to both angiogenesis (which enables tumors to grow) and invasion and metastasis (which accounts for most cancer mortality). Angiex's lead drug, AGX101, can simultaneously eliminate angiogenic vessels and kill invasive and metastatic tumor cells. It has dosed safely to high levels (> 6 mg/kg) and shows promising efficacy.
Interested in this innovator?
Send a short message. We’ll pass it to Angiex, Inc. with your name and email, so they can reply.
Request an introduction
Create an account or log in to send this request. Already a member? Log in
Introductions to innovators are open to innovators, investors, mentors and corporates.